Skip to content
Back to FULC

Fulcrum Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
14
Purchases
6
Sales
8
Purchase value
$1.49M
Sale value
$58.98M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Tang Capital Management LLC10% owner
Tang Kevin10% owner
4
Filed Jul 20, 2026Period of report Jul 16, 20260001178579-26-000016
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJul 17, 2026
Common StockF3F250,945$3.52$179.33K7,080,945IndirectSee Footnote
PurchaseJul 16, 2026
Common StockF1F2116,671$3.56$415.35K7,030,000IndirectSee Footnote
Filing footnotes · 3
  1. F1The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3.
  2. F2Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
  3. F3These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55.
Open on SEC EDGAR
Tang Capital Management LLC10% owner
Tang Kevin10% owner
4
Filed Jul 15, 2026Period of report Jul 13, 20260001178579-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJul 15, 2026
Common StockF5F2107,377$3.56$382.26K6,913,329IndirectSee Footnote
PurchaseJul 14, 2026
Common StockF3F253,651$3.56$191.00K6,730,000IndirectSee Footnote
PurchaseJul 14, 2026
Common StockF4F275,952$3.58$271.91K6,805,952IndirectSee Footnote
PurchaseJul 13, 2026
Common StockF1F212,966$3.54$45.90K6,676,349IndirectSee Footnote
Filing footnotes · 5
  1. F1The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.55. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 5.
  2. F2Tang Capital Partners, LP ("TCP") beneficially owns 1,630,142 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
  3. F3These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.60.
  4. F4These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.60.
  5. F5These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60.
Open on SEC EDGAR
Alan EzekowitzDirector
4
Filed Jun 30, 2026Period of report Jun 26, 20260001193125-26-290622
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 26, 2026
Common StockF1F218,000$3.6452$65.61K10,927Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Robert J GouldDirector
4
Filed Feb 4, 2026Period of report Feb 2, 20260001193125-26-037573
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common StockF1F215,000$10.7238$160.86K454,864Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $11.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR
Robert J GouldDirector
4/AAmendment
Filed Feb 4, 2026Period of report Jan 2, 20260001193125-26-037606
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 2, 2026
Common StockF1F215,000$10.8726$163.09K469,864Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. This Form 4/A corrects the weighted average price indicated in the Form 4 submitted on January 6, 2026 from $11.8726 to $10.8726.
Open on SEC EDGAR
Curtis Gale OltmansChief Legal Officer
4
Filed Dec 17, 2025Period of report Dec 15, 20250001193125-25-322740
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 15, 2025
Common StockF1F23,452$12.92$44.60K10,252Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
  2. F2Includes 10,252 shares that were previously acquired under the Issuer's employee stock purchase plan.
Open on SEC EDGAR
Kolchinsky Peter10% owner
RA Capital Healthcare Fund LP10% owner
RA Capital Management, L.P.10% owner
Shah Rajeev M.10% owner
4
Filed Dec 10, 2025Period of report Dec 8, 20250001231919-25-000596
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Common StockF1F2F31,377,020$13.33$18.36M8,852,079IndirectSee footnotes
SaleDec 8, 2025
Common StockF4F2F32,706,397$14.28$38.65M6,145,682IndirectSee footnotes
SaleDec 8, 2025
Common StockF5F2F391,722$14.98$1.37M6,053,960IndirectSee footnotes
Filing footnotes · 5
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.81 to $13.8099 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  3. F3Held directly by the Fund.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.805 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.81 to $15.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Robert J GouldDirector
4
Filed Nov 21, 2025Period of report Nov 19, 20250001193125-25-291392
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 19, 2025
Common StockF1F215,000$11.033$165.50K484,864Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $11.18, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.